Clinical Trials Directory

Trials / Terminated

TerminatedNCT00069849

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
64 (planned)
Sponsor
Abbott · Industry
Sex
All
Age
50 Years – 85 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the safety and efficacy of 2 mg, 4 mg, and 20 mg of ABT-089 BID to placebo in adults with Alzheimer's disease.

Conditions

Interventions

TypeNameDescription
DRUGABT-089

Timeline

Start date
2003-07-01
First posted
2003-10-02
Last updated
2006-09-04

Locations

8 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00069849. Inclusion in this directory is not an endorsement.